Axsome Therapeutics (AXSM) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 74.9% versus a gain of 43.3%. Over five years, KRYS leads with a +571.8% price change compared with +324.1% for AXSM. Krystal Biotech is the larger company by market cap ($9.69 billion vs $8.91 billion), about 1.1 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +33.9%).
On valuation, Krystal Biotech trades at a lower forward P/E (35.3x vs 36.2x for Axsome Therapeutics). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | KRYS |
|---|---|---|
| Share price | $170.08 | $327.30 |
| Market cap | $8.91B | $9.69B |
| 1-day change | -1.67% | +0.84% |
| YTD return | -6.88% | +32.76% |
| 1-year return | +43.27% | +74.86% |
| 5-year return | +324.14% | +571.80% |
| P/E ratio (TTM) | — | 41.02 |
| Forward P/E | 36.17 | 35.33 |
| EPS (TTM) | $-3.74 | $7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $389.13M |
| Revenue growth (YoY) | +65.55% | +33.94% |
| Net income (latest FY) | $-183.17M | $204.83M |
| Gross margin | 92.56% | — |
| Operating margin | -26.12% | 41.45% |
| Net margin | -28.69% | 52.64% |
| 52-week high | $260.19 | $382.54 |
| 52-week low | $119.20 | $179.19 |
| Distance from 52-week high | -34.63% | -14.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.35% | +19.80% |
| Average volume | 712.30K | 381.18K |
| Shares outstanding | 52.38M | 29.60M |
| Employees | 1,346 | 295 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed AXSM by 31.6 percentage points over the past year.
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +33.94%).
- The two companies sit in different sectors: Axsome Therapeutics in Health Care and Krystal Biotech in Healthcare.
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Healthcare · Biotechnology · 295 employees
AXSM vs KRYS FAQ
Which is bigger, Axsome Therapeutics or Krystal Biotech?
Krystal Biotech (KRYS) is larger, with a market capitalization of $9.69B compared with $8.91B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or KRYS?
KRYS returned +74.86% over the past 12 months, compared with +43.27% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Krystal Biotech in the same industry?
No. Axsome Therapeutics is in the Health Care sector, while Krystal Biotech is in Healthcare.